[1]
|
FDA approves anti-LAG3 checkpoint[J]. Nat Biotechnol, 2022, 40: 625. |
[2]
|
Yi M, Zheng X, Niu M, et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions[J]. Mol Cancer, 2022, 21: 28. doi: 10.1186/s12943-021-01489-2 |
[3]
|
de Miguel M, Calvo E. Clinical Challenges of Immune Checkpoint Inhibitors[J]. Cancer Cell, 2020, 38: 326-333. doi: 10.1016/j.ccell.2020.07.004 |
[4]
|
Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase Ⅲ KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up[J]. Ann Oncol, 2019, 30: 970-976. doi: 10.1093/annonc/mdz127 |
[5]
|
McLaughlin M, Patin EC, Pedersen M, et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy[J]. Nat Rev Cancer, 2020, 20: 203-217. doi: 10.1038/s41568-020-0246-1 |
[6]
|
Pouget JP, Lozza C, Deshayes E, et al. Introduction to radiobiology of targeted radionuclide therapy[J]. Front Med (Lausanne), 2015, 2: 12. |
[7]
|
Deng L, Liang H, Xu M, et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type Ⅰ Interferon-Dependent Antitumor Immunity in Immunogenic Tumors[J]. Immunity, 2014, 41: 843-852. doi: 10.1016/j.immuni.2014.10.019 |
[8]
|
Zhang X, Zhang H, Zhang J, et al. The paradoxical role of radiation-induced cGAS-STING signalling network in tumour immunity[J]. Immunology, 2023, 168: 375-388. doi: 10.1111/imm.13592 |
[9]
|
Lan Y, Moustafa M, Knoll M, et al. Simultaneous targeting of TGF-beta/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion[J]. Cancer Cell, 2021, 39: 1388-403. e10. doi: 10.1016/j.ccell.2021.08.008 |
[10]
|
Sha CM, Lehrer EJ, Hwang C, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis[J]. Radiother Oncol, 2020, 151: 141-148. doi: 10.1016/j.radonc.2020.07.035 |
[11]
|
Procureur A, Simonaggio A, Bibault JE, et al. Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments[J]. Cancers (Basel), 2021, 13: 678. doi: 10.3390/cancers13040678 |
[12]
|
Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520: 373-377. doi: 10.1038/nature14292 |
[13]
|
Formenti SC, Demaria S. Systemic effects of local radiotherapy[J]. Lancet Oncol, 2009, 10: 718-726. doi: 10.1016/S1470-2045(09)70082-8 |
[14]
|
Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade[J]. Nat Med, 2018, 24: 1845-1851. doi: 10.1038/s41591-018-0232-2 |
[15]
|
Kleinendorst SC, Oosterwijk E, Bussink J, et al. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment[J]. Clin Cancer Res, 2022, 28: 3652-3657. doi: 10.1158/1078-0432.CCR-21-4332 |
[16]
|
Sun Q, Li J, Ding Z, et al. Radiopharmaceuticals heat anti-tumor immunity[J]. Theranostics, 2023, 13: 767-786. doi: 10.7150/thno.79806 |
[17]
|
Rouanet J, Benboubker V, Akil H, et al. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy[J]. Cancer Immunol Immunother, 2020, 69: 2075-2088. doi: 10.1007/s00262-020-02606-8 |
[18]
|
Jagodinsky JC, Jin WJ, Bates AM, et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy[J]. Theranostics, 2021, 11: 6120-6137. doi: 10.7150/thno.54881 |
[19]
|
Patel RB, Hernandez R, Carlson P, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade[J]. Sci Transl Med, 2021, 13: eabb3631. doi: 10.1126/scitranslmed.abb3631 |
[20]
|
Grzmil M, Boersema P, Sharma A, et al. Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)[J]. J Hematol Oncol, 2022, 15: 123. doi: 10.1186/s13045-022-01343-y |
[21]
|
Zhang J, Yang M, Fan X, et al. Biomimetic radiosensitizers unlock radiogenetics for local interstitial radiotherapy to activate systematic immune responses and resist tumor metastasis[J]. J Nanobiotechnology, 2022, 20: 103. doi: 10.1186/s12951-022-01324-w |
[22]
|
Brown R, Hernandez R, Grudzinski JJ, et al. Ability of Molecular Targeted Radionucleotide Therapy and Anti-CTLA-4 to Prevent Spontaneous Metastases in a Preclinical Lewis Lung Carcinoma Model[J]. Int J Radiat Oncol Biol Phys, 2019, 105: E498-E499. |
[23]
|
Potluri HK, Ferreira CA, Grudzinski J, et al. Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors[J]. J Immunother Cancer, 2022, 10: e005060. doi: 10.1136/jitc-2022-005060 |
[24]
|
Lutetium (Lu-177) Dotatate Approved by FDA[J]. Cancer Discov, 2018, 8: OF2. |
[25]
|
Fallah J, Agrawal S, Gittleman H, et al. FDA Approval Summary: lutetium (Lu-177) vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2023, 29: 1651-1657. doi: 10.1158/1078-0432.CCR-22-2875 |
[26]
|
Kim C, Liu SV, Subramaniam DS, et al. Phase Ⅰ study of the 177Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung[J]. J Immunother Cancer, 2020, 8: e000980. doi: 10.1136/jitc-2020-000980 |
[27]
|
Ferdinandus J, Fendler WP, Lueckerath K, et al. Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma[J]. J Nucl Med, 2022, 63: 396-398. doi: 10.2967/jnumed.121.262344 |
[28]
|
Lin AL, Tabar V, Young RJ, et al. Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma[J]. J Endocr Soc, 2021, 5: bvab133. doi: 10.1210/jendso/bvab133 |
[29]
|
Prasad V, Zengerling F, Steinacker JP, et al. First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients[J]. J Nucl Med, 2021, 62: 975-978. doi: 10.2967/jnumed.120.249029 |
[30]
|
Chen H, Zhao L, Fu K, et al. Integrin αυβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergis-tically enhances anti-tumor efficacy[J]. Theranostics, 2019, 9: 7948-7960. doi: 10.7150/thno.39203 |
[31]
|
Wen XJ, Zeng XY, Shi CR, et al. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy[J]. Adv Ther, 2022, 6: 2200193. |
[32]
|
Wen X, Zeng X, Liu J, et al. Synergism of 64Cu-Labeled RGD with Anti-PD-L1 Immunotherapy for the Long-Acting Antitumor Effect[J]. Bioconjug Chem, 2022, 33: 2170-2179. doi: 10.1021/acs.bioconjchem.2c00408 |
[33]
|
Guzik P, Siwowska K, Fang HY, et al. Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy-a preclinical study using a syngeneic breast cancer model[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 984-994. doi: 10.1007/s00259-020-05054-9 |
[34]
|
Ren J, Xu M, Chen J, et al. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled alphaPD-L1 antibody[J]. Theranostics, 2021, 11: 304-315. doi: 10.7150/thno.45540 |
[35]
|
Malo ME, Allen KJH, Jiao R, et al. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmun-otherapy and Immunotherapy in Experimental Melanoma[J]. Int J Mol Sci, 2020, 21: 8721. doi: 10.3390/ijms21228721 |
[36]
|
Choi J, Beaino W, Fecek RJ, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma[J]. J Nucl Med, 2018, 59: 1843-1849. doi: 10.2967/jnumed.118.209510 |
[37]
|
Vito A, Rathmann S, Mercanti N, et al. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer[J]. Int J Mol Sci, 2021, 22: 4843. doi: 10.3390/ijms22094843 |
[38]
|
Stap J, Krawczyk PM, Van Oven CH, et al. Induction of linear tracks of DNA double-strand breaks by alpha-particle irradiation of cells[J]. Nat Methods, 2008, 5: 261-266. doi: 10.1038/nmeth.f.206 |
[39]
|
Czernin J, Current K, Mona CE, et al. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer[J]. J Nucl Med, 2021, 62: 228-231. doi: 10.2967/jnumed.120.246041 |
[40]
|
Josefsson A, Nedrow JR, Park S, et al. Combining alpha-particle radiopharmaceutical therapy using Actinium-225 and immunotherapy with anti-PD-L1 antibodies in a murine immunocompetent metastatic breast cancer model[J]. Cancer Res, 2016, 76: 3052. doi: 10.1158/1538-7445.AM2016-3052 |
[41]
|
Dabagian H, Taghvaee T, Martorano P, et al. PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma[J]. ACS Pharmacol Transl Sci, 2021, 4: 344-351. doi: 10.1021/acsptsci.0c00206 |
[42]
|
Zhang J, Li F, Yin Y, et al. Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression[J]. Biomater Res, 2022, 26: 44. doi: 10.1186/s40824-022-00290-6 |
[43]
|
Malamas AS, Gameiro SR, Knudson KM, et al. Sublethal exposure to alpha radiation 223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation[J]. Oncotarget, 2016, 7: 86937-86947. doi: 10.18632/oncotarget.13520 |
[44]
|
Creemers JHA, van der Doelen MJ, van Wilpe S, et al. Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer[J]. Front Oncol, 2021, 11: 667658. doi: 10.3389/fonc.2021.667658 |
[45]
|
Vardaki I, Corn P, Gentile E, et al. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment[J]. Clin Cancer Res, 2021, 27: 3253-3264. doi: 10.1158/1078-0432.CCR-20-4790 |
[46]
|
Fong L, Morris MJ, Sartor O, et al. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer[J]. Clin Cancer Res, 2021, 27: 4746-4756. doi: 10.1158/1078-0432.CCR-21-0063 |
[47]
|
Li M, Liu D, Lee D, et al. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma[J]. Cancers (Basel), 2021, 13: 3676. doi: 10.3390/cancers13153676 |
[48]
|
Nosanchuk JD, Jeyakumar A, Ray A, et al. Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy[J]. Sci Rep, 2018, 8: 5466. doi: 10.1038/s41598-018-23889-z |
[49]
|
Perrin J, Capitao M, Allard M, et al. Targeted Alpha Particle Therapy Remodels the Tumor Microenvironment and Improves Efficacy of Immunotherapy[J]. Int J Radiat Oncol Biol Phys, 2022, 112: 790-801. doi: 10.1016/j.ijrobp.2021.10.013 |
[50]
|
Gorin JB, Menager J, Gouard S, et al. Antitumor immunity induced after alpha irradiation[J]. Neoplasia, 2014, 16: 319-328. doi: 10.1016/j.neo.2014.04.002 |
[51]
|
Lejeune P, Cruciani V, Berg-Larsen A, et al. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy[J]. J Immunother Cancer, 2021, 9: e002387. doi: 10.1136/jitc-2021-002387 |
[52]
|
Hagemann UB, Ellingsen C, Schuhmacher J, et al. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers[J]. Clin Cancer Res, 2019, 25: 4723-4734. doi: 10.1158/1078-0432.CCR-18-3476 |
[53]
|
Moadel RM, Nguyen AV, Lin EY, et al. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer[J]. Breast Cancer Res, 2003, 5: R199-R205. doi: 10.1186/bcr643 |
[54]
|
Moadel RM, Weldon RH, Katz EB, et al. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose[J]. Cancer Res, 2005, 65: 698-702. doi: 10.1158/0008-5472.698.65.3 |
[55]
|
Fang S, Wang J, Jiang H, et al. Experimental study on the therapeutic effect of positron emission tomography agent[18F]-labeled 2-deoxy-2-fluoro-d-glucose in a colon cancer mouse model[J]. Cancer Biother Radiopharm, 2010, 25: 733-740. |
[56]
|
Wen X, Shi C, Zeng X, et al. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect[J]. Clin Cancer Res, 2022, 28: 2923-2937. doi: 10.1158/1078-0432.CCR-22-0159 |
[57]
|
文雪君, 周吴昊, 郭志德, 等. 整合素αυβ3靶向放射性药物99mTc-RGD联合抗PD-L1肿瘤免疫治疗增强抗肿瘤效果的研究[J]. 协和医学杂志, 2023, 14: 766-773. doi: 10.12290/xhyxzz.2023-0155 |
[58]
|
Wen X, Zeng X, Cheng X, et al. PD-L1-Targeted Radionuclide Therapy Combined with alpha PD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect[J]. Mol Pharm, 2022, 19: 3612-3622. doi: 10.1021/acs.molpharmaceut.2c00281 |
[59]
|
Gutfilen B, Souza SA, Valentini G. Copper-64: a real theranostic agent[J]. Drug Des Devel Ther, 2018, 12: 3235-3245. doi: 10.2147/DDDT.S170879 |